Natural Killer (NK) Cell Transplantation for AML

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Jude Children's Research Hospital
• Treatments: Clofarabine; Cyclophosphamide; Etoposide; Etoposide phosphate; Fludarabine; Fludarabine phosphate; Interleukin-2

Criteria

Inclusion Criteria:

• Participants with AML that is in complete remission, is relapsed or refractory, or with increasing minimal residual disease.

• Participants in complete remission must have recovered from toxicity of previous therapy and have evidence of bone marrow recovery

• Participants who had prior stem cell transplant (SCT) must have no evidence of GVHD and 60 or more days have elapsed since the SCT.

Exclusion Criteria:

• Participants who are pregnant

• Participants with inadequate renal, liver, or pulmonary functions